pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CYTB323J12201
Phase 2 · small molecule · Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)
CYTB323J12201 for Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN) is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CYTB323J12201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)
- Status
- active
- Trials
- 1